Orforglipron Dosage Guide
55/100 confidenceComplete guide to Orforglipron dosing protocols, administration methods, and safety considerations for research purposes.
NOT Medical Advice
The dosage and calculator information provided is for educational and research purposes only. Peptides are not approved by the FDA for human use. Individual responses vary significantly. Always consult with a qualified healthcare professional before making any decisions related to peptide research or use.
Dosage Overview
Dose Range
12 mg - 45 mg
Route
oral
Frequency
1x daily
Detailed Dosage Information
Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established.
Administration Method
Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available.
Research Backing
Phase 2 trial (NEJM, Frias et al. 2023): up to 14.7% weight loss at 36 weeks (45 mg). Phase 3 ATTAIN program ongoing. Eli Lilly pipeline. Analysts project $16B annual sales by 2031.
Side Effects to Monitor
Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%.
Safety Considerations & Risks
Pre-approval medication — full safety profile not yet established. Thyroid C-cell tumor risk not yet fully assessed in humans (positive signal in rodent studies expected). Hepatic effects under evaluation. No long-term safety data beyond 36 weeks. Risk of drug-drug interactions with oral medications (GLP-1 effects on gastric emptying may alter absorption of other drugs).